US Bancorp
BEAM icon

US Bancorp’s Beam Therapeutics BEAM Stock Holding History

US Bancorp’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$506K Buy
14,751
+79
+0.5% +$2.38K ﹤0.01% 1564
2026
Q1 		$350K Buy
14,672
+13,895
+1,788% +$386K ﹤0.01% 1690
2025
Q4 		$21.5K Hold
777
– – ﹤0.01% 3053
2025
Q3 		$18.9K Buy
777
+185
+31% +$3.68K ﹤0.01% 3093
2025
Q2 		$10.1K Sell
592
-64
-10% -$1.11K ﹤0.01% 3420
2025
Q1 		$12.8K Buy
656
+348
+113% +$9.12K ﹤0.01% 3351
2024
Q4 		$7.64K Sell
308
-276
-47% -$7.04K ﹤0.01% 3514
2024
Q3 		$14.3K Sell
584
-1,651
-74% -$42.7K ﹤0.01% 3235
2024
Q2 		$52.4K Sell
2,235
-9
-0.4% -$221 ﹤0.01% 2653
2024
Q1 		$74.1K Buy
2,244
+227
+11% +$7.07K ﹤0.01% 2499
2023
Q4 		$54.9K Sell
2,017
-7
-0.3% -$174 ﹤0.01% 2627
2023
Q3 		$48.7K Buy
2,024
+1,707
+538% +$45.8K ﹤0.01% 2453
2023
Q2 		$10.1K Sell
317
-294
-48% -$9.54K ﹤0.01% 3257
2023
Q1 		$18.7K Buy
611
+189
+45% +$7.46K ﹤0.01% 3027
2022
Q4 		$16.5K Sell
422
-6,287
-94% -$282K ﹤0.01% 3087
2022
Q3 		$319K Sell
6,709
-539
-7% -$30.7K ﹤0.01% 1606
2022
Q2 		$282K Sell
7,248
-3,554
-33% -$141K ﹤0.01% 1727
2022
Q1 		$619K Buy
10,802
+571
+6% +$37.5K ﹤0.01% 1433
2021
Q4 		$815K Buy
10,231
+600
+6% +$51.4K ﹤0.01% 1294
2021
Q3 		$839K Buy
9,631
+153
+2% +$15.4K ﹤0.01% 1269
2021
Q2 		$1.22M Buy
9,478
+4,441
+88% +$354K ﹤0.01% 1106
2021
Q1 		$403K Buy
5,037
+4,037
+404% +$384K ﹤0.01% 1608
2020
Q4 		$82K Sell
1,000
-2,000
-67% -$98.4K ﹤0.01% 2307
2020
Q3 		$74K Buy
+3,000
New +$74.4K ﹤0.01% 2226

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

US Bancorp's BEAM Position: Q2 2026 in Review

US Bancorp increased its Beam Therapeutics (BEAM) stake by 0.54% in Q2 2026, buying an estimated $2.38K and bringing the position to 14,751 shares worth $506K. The position accounts for ﹤0.01% of the portfolio, ranked #1564.

US Bancorp first reported a position in BEAM in Q3 2020 and has held it in 24 quarters since. The position peaked at $1.22M in Q2 2021. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • US Bancorp held 14,751 shares of Beam Therapeutics worth $506K as of Q2 2026.
  • US Bancorp bought 79 Beam Therapeutics shares in Q2 2026, an estimated $2.38K.
  • Beam Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1564 holding.
  • US Bancorp first reported a position in Beam Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • US Bancorp's Beam Therapeutics position peaked at $1.22M in Q2 2021.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.